Esperion Therapeutics, Inc. Announces Exercise of Underwriters' Over-Allotment Option for Initial Public Offering

Published: Jul 12, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PLYMOUTH, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that the underwriters of its recently completed initial public offering (IPO) have exercised in full their option to purchase an additional 750,000 shares of common stock from Esperion to cover over-allotments. The sale of the additional shares closed on July 11, 2013. Including proceeds from the sale of the additional shares, the net proceeds to Esperion from the IPO are expected to be $72.8 million after deducting underwriting discounts and commissions and estimated offering expenses payable by Esperion.

Help employers find you! Check out all the jobs and post your resume.

Back to news